Zobrazeno 1 - 10
of 14
pro vyhledávání: '"Olaposi Yomade"'
Autor:
Marvin Ritter, Olaposi Yomade, Ben-Ole Holtz, Stefanie Deinhardt-Emmer, Aaron Lawson McLean, Stefanie Hartinger, Julia Bechwar, Matthias Schwab, André Huss, Christian Mawrin, Hubertus Axer, Karin G. Schrenk, Philipp A. Reuken, Irina Mäurer
Publikováno v:
Frontiers in Immunology, Vol 15 (2024)
BackgroundThe hepatitis E virus (HEV) can cause acute viral hepatitis with or without neurological manifestations, and occasionally progresses to chronic infection in immunocompromised individuals. The management of chronic HEV infection in cancer pa
Externí odkaz:
https://doaj.org/article/677c0bb5042e4785b2ce211cf129b68a
Autor:
Annamaria Brioli, Franziska Braese, Olaposi Yomade, Inken Hilgendorf, Thomas Ernst, Theresa Maria Nägler, Andreas Hochhaus, Marie Von Lilienfeld-Toal
Publikováno v:
HemaSphere, Vol 7, p e2621605 (2023)
Externí odkaz:
https://doaj.org/article/eec2d41888c2435b8eae52dde1194502
Autor:
Annamaria Brioli, Antje Wyrwa, Ulrike Rüddel, Olaposi Yomade, Udo Lindig, Wiebke Franz, Hans-Heinrich Wacker, Nikolaus Gaßler, Stefan Schweyer, Ha-Yeun Chung, Hubertus Axer, Otto W. Witte, Andreas Hochhaus, Karin G. Schrenk
Publikováno v:
Annals of Hematology. 102:239-242
Autor:
Sebastian Scholl, Romy Tober, Ulf Schnetzke, Maximilian Fleischmann, Olaposi Yomade, Karin G Schrenk, Jakob F Hammersen, Anita Glaser, Christian Thiede, Andreas Hochhaus
Publikováno v:
Journal of Cancer Research and Clinical Oncology. 149:1569-1583
Background Infectious complications reflect a major challenge in the treatment of patients with acute myeloid leukemia (AML). Both induction chemotherapy and epigenetic treatment with hypomethylating agents (HMA) are associated with severe infections
Autor:
Annamaria Brioli, Theresa Maria Nägler, Olaposi Yomade, Maria Madeleine Rüthrich, Sebastian Scholl, Jochen J. Frietsch, Inken Hilgendorf, Thomas Ernst, Herbert Gottfried Sayer, Andreas Hochhaus, Lars-Olof Mügge, Marie von Lilienfeld-Toal
Publikováno v:
Oncology research and treatment. 45(9)
Introduction: Multiple myeloma (MM) is a plasma cell disease that affects more men than women. Although there is an obvious imbalance in incidence, knowledge of differences in biology and outcome between the sexes is surprisingly rare. Methods: We pe
Autor:
Marie von Lilienfeld-Toal, Paola Rucci, Thomas Ernst, Felix Vom Hofe, Olaposi Yomade, Andreas Hochhaus, Herbert G. Sayer, Sebastian Scholl, Annamaria Brioli, Lars-Olof Mügge, Inken Hilgendorf
Autologous stem cell transplantation (ASCT) conditioned with melphalan 200 mg/m2 (Mel200) is standard of care for young multiple myeloma (MM) patients. Lower doses of melphalan (MelRed) have been used to reduce toxicity, although data regarding their
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e7550734e858264abf03b44648ccf39f
http://hdl.handle.net/11585/794247
http://hdl.handle.net/11585/794247
Autor:
Christof Kloos, Gunter Wolf, Christoph Werner, Olaposi Yomade, Andreas Hochhaus, Schrenk Karin Gabriela, Sebastian Schmidt
Publikováno v:
Endocrine Abstracts.
Autor:
Annamaria, Brioli, Felix, Vom Hofe, Paola, Rucci, Thomas, Ernst, Olaposi, Yomade, Inken, Hilgendorf, Sebastian, Scholl, Herbert, Sayer, Lars-Olof, Mügge, Andreas, Hochhaus, Marie, von Lilienfeld-Toal
Publikováno v:
Bone marrow transplantation. 56(5)
Autologous stem cell transplantation (ASCT) conditioned with melphalan 200 mg/m
Autor:
Thomas Neumuth, Anne Sophie Kubasch, Alexander Oeser, Uwe Platzbecker, Andreas Hochhaus, M. Merz, Olaposi Yomade, Nora Grieb
Publikováno v:
Blood. 138:2953-2953
AK+NG eq. cont. Introduction Management of multiple myeloma (MM) improved dramatically in the last decade. However, prognosis is still poor for high-risk MM patients experiencing early relapse (ER) within 12 months after primary diagnosis. While some